p38 MAPK

p38 MAPK inhibitor, FR167653, a potent therapy against PTHrP-induced osteoclastogenesis and bone resorption-related diseases

Sep 07 2011

Study on mechanism indecates that PTHrP stimulates osteoclastogenesis by increasing receptor activator of NF-kB ligand (RANKL) expression. p38 MAPK is required for osteoclast differentiation. This implies the existence of relationship between p38 MAPK and PTHrP in osteoclastogenesis. >Read the Full Post

( 54 ) Comments | ( 578 ) Read

Munoz, L. and A. J. Ammit (2010). "Targeting p38 MAPK pathway for the treatment of Alzheimer

Jul 14 2011

This is an introduction of the relationship between p38 MAPK and Alzheimer's disease because p38 MAPK plays an important role in Alzheimer's disease. It also list the p38 MAPK inhibitors Alzheimer's disease patients could benefit from. >Read the Full Post

( 0 ) Comments | ( 82 ) Read

Contact or follow me!

  • Subscribe by Email

Archives